Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Am J Kidney Dis. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2692133

Does Inflammation Fuel the Fire in Chronic Kidney Disease?

Dena E. Rifkin, MD, MS and Mark J. Sarnak, MD, MS

Since the landmark 1961 publication from the Framingham Study identifying smoking as a modifiable cardiac risk factor,1 the field of preventive cardiology has burgeoned, and the science of risk factor analysis 2 has been applied to other chronic diseases. Of most interest is the identification of risk factors that are not only predictive of disease but are also both modifiable and causal: for the example of cardiovascular disease (CVD), gender is predictive, but non-modifiable; homocysteine levels are predictive, modifiable, but not necessarily causal; and hypertension is predictive, modifiable, and causal, in that treatment reliably reduces the risk of disease.

For chronic kidney disease (CKD), risk factors can be divided into risk of initiation of kidney damage and risk for progression of established kidney damage. Unlike CVD, where identifiable ‘events’ demarcate the transition from risk and subclinical disease to overt disease, CKD is typically asymptomatic, and markers of damage, such as albuminuria, are few. Thus for most patients, CKD is first diagnosed as an estimated glomerular filtration rate (GFR) less than 60ml/min/1.73 m2. This diagnosis is a point on a continuous spectrum, so that passing the CKD threshold is more likely a sign of progression rather than initiation. Despite the continuous nature of kidney function loss, passing below an estimated GFR of 60 ml/min/1.73 m2 – well prior to end-stage renal disease (ESRD) -- has been associated with a myriad of complications, including CVD,3,4 muscle weakness,5 cognitive abnormalities,6 hospitalizations,3 physical impairment7 and high cost.8 Thus, finding new targets for early treatment and prevention of CKD would be a major advance.

On a population basis, a number of predictive, modifiable and causal risk factors have been identified for kidney disease progression: of these, diabetes, hypertension, and vascular disease9,10 are the most common illnesses, while smoking and non steroidal anti-inflammatory use (NSAID) use11 are the most common exposures.12,13 However, these factors do not entirely explain the population prevalence of CKD.10

A host of inflammatory peptides, including C-reactive protein, fibrinogen, D-dimer, and many others, have been proposed as risk factors for CVD;14,15 many of these are not modifiable or causal, although recent data suggest that treatment of inflammation in those with elevated C-reactive protein may in fact lower cardiac risk.16 Given the many similarities between risk factor profiles for cardiac and kidney diseases, it is reasonable to ask whether inflammation promotes the progression of kidney disease. The similarities between atherosclerosis and glomerulosclerosis have been proposed by various investigators; both atherosclerosis and glomerulosclerosis lead to influx of monocytes, production of lipid-laden macrophages, an increased presence of cholesterol and cholesterol esters, proliferation of contractile cells and matrix expansion resulting in fibrosis.17,18 Biological studies suggest that inflammation plays a key role in both processes,19,20 and subclinical measures of atherosclerosis have been associated with kidney function decline.21 Chronic kidney disease and an inflammatory milieu are often found together,22 with a high prevalence of increased c-reactive protein (CRP), fibrinogen and white blood cell (WBC) count, and low albumin noted in stages 3–5 CKD.2326 The causal links between the two have not however been established in epidemiological studies.

Several analyses of large cohort studies have attempted to address these issues by examining inflammation and subsequent kidney disease outcomes. In the National Health And Nutrition Examination Study, low albumin and high white count were associated with future ESRD or death from kidney disease.27 In the Cardiovascular Health Study (CHS) cohort, older adults with high levels of CRP, factor VII, fibrinogen, WBC count, and hemoglobin or low levels of albumin had a greater risk of progressive loss of kidney function as assessed by a change of more than 3 ml/min/1.73 m2/year over 7 years.28 Post-hoc analysis of the Cholesterol and Recurrent Events Trial suggested that, in those with established CKD, high CRP and soluble TNF receptor II levels were associated with faster progression.29 However, these associations have not been previously been explored in a younger population with normal kidney function at baseline and multiple measures of kidney function over time to define incident CKD.

In this issue of AJKD, Bash and colleagues [cite] use 14 yr follow up from the Atherosclerosis Risk in Communities (ARIC) study to provide insight into the links between inflammation and incident CKD, as defined by estimated GFR (using the MDRD equation) less than 60 ml/min/1.73 m2 or a ICD-9 code reflective of CKD; albuminuria was not measured in this study, and therefore was not used as part of the definition of CKD. The ARIC cohort included a middle-aged (45–64) group of white and African American men and women, drawn from 4 U.S. cities; those with baseline CKD were excluded, leaving a sample of 14,854 individuals. Six different markers of inflammation and hemostasis (white blood cell count, fibrinogen, von Willebrand factor, factor VIIc, factor VIIIc, and serum albumin) were assessed. The findings were striking: even after adjustment for known risk factors and baseline estimated GFR, five of the six analytes tested had significant associations with incident CKD. Factor VIIc (which was associated with incident CKD in CHS) was not found to have a significant association in ARIC. For the other analytes, the highest quartile of each marker (except for albumin where it was the lowest quartile) was associated with a 20–40% increase in the adjusted risk of incident CKD in comparison with the lowest quartile; graded associations were seen with incident CKD risk across the full measured range.

The large multi-racial cohort, long follow-up, and robust results across different definitions of CKD and across the various inflammatory markers are major strengths of this work. Most studies of incident CKD have had either estimates of GFR6,9 or diagnostic codes for CKD-related hospitalizations,27 but not both; this limits the specificity or sensitivity, respectively, of study findings. The results of this study were similar using either definition but were stronger using diagnostic codes, as expected from others’ findings that diagnostic codes are more specific and tend to detect more advanced CKD.30

A few limitations deserve mention. Although the authors studied multiple different inflammatory markers, they did not include CRP, which is currently the most commonly measured inflammatory marker in clinical practice.31 It is not clear, outside of the research setting, whether measurement of multiple markers is required to define inflammation or whether one marker would suffice. In this study, for instance, the correlation between factor VIIIC and von Willebrand factor is 0.7, suggesting that only one of these would need to be measured in practice; correlations between the other analytes are weaker and it is not clear which combination of these would be of most value. We would infer that serum albumin would be the best single analyte to measure, as the associations with increased risk of CKD were significant even with minimally decreased levels of albumin, and given that these risks were minimally attenuated by multivariate adjustment; however, albumin level is less specific for inflammation or thrombosis than some of the other markers, and may be confounded by other illnesses.

An additional question that is not specifically addressed in this manuscript is the fraction of CKD risk attributable to this constellation of inflammatory markers versus other, traditional markers of CVD. This would be important in directing potential therapeutic interventions; for example, if traditional factors account on a population basis for 95% of the risk of incident CKD, or if inflammation proves to be a relatively minor mediator of traditional risk factors32, then inflammation may only be of academic significance in promoting incident CKD. To move from a study like this one, which assesses the relative risk associated with inflammation, to predictive use of inflammatory markers to identify individuals at risk for CKD, studies of the test characteristics of the markers would be needed including receiver-operator characteristic curves, discrimination, and test calibration, and a substantial addition to known risk factors would be required.33

Risk associations such as those found in this work may be confounded by residual disease (e.g. more severe diabetes not adequately characterized by a binary variable might be associated with inflammation and with incident CKD) or by unmeasured disease such as subclinical cardiovascular disease and in particular albuminuria (as acknowledged by the authors). The ‘non-CKD’ cohort in this study is defined by eGFR > 60 ml/min/1.73 m2; this cohort includes a subgroup of individuals with albuminuria who may be more likely to progress than those with estimated GFR < 60 ml/min/1.73 m2 and no albuminuria.34,35 Furthermore, albuminuria is independently associated with inflammatory markers such as fibrinogen levels.36 Thus, the association of inflammatory markers with incident CKD may be confounded by unmeasured albuminuria at baseline.

The important findings of this study should be replicated in a population with data on albuminuria, and the comparative importance of inflammation versus other risk factors should be assessed. If a strong and independent association with a high attributable risk due to inflammation is demonstrated, the value of inflammatory markers in predicting CKD should be assessed, and trials using anti-inflammatory therapies to prevent progression or initiation of CKD should be considered. Given what we know about the morbidity and mortality associated with chronic kidney disease, the identification of inflammation as a predictive, modifiable, and treatable risk factor would be welcome news indeed.




Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J., 3rd Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50. [PubMed]
2. Stampfer MJ, Ridker PM, Dzau VJ. Risk factor criteria. Circulation. 2004;109:IV3–5. [PubMed]
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. [PubMed]
4. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–9. [PubMed]
5. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2006;61:1059–64. [PubMed]
6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40. [PubMed]
7. Fried LF, Lee JS, Shlipak M, Chertow GM, Green C, Ding J, Harris T, Newman AB. Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc. 2006;54:750–6. [PubMed]
8. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol. 2004;15:1363–4. [PubMed]
9. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ, Weiner DE. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–6. [PubMed]
10. Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, Gipson D, Colindres RE, Kshirsagar AV. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med. 2007;167:374–81. [PubMed]
11. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(280):e1–7. [PubMed]
12. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int. 2000;57:2072–9. [PubMed]
13. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934–41. [PubMed]
14. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6–19. [PubMed]
15. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–610. [PubMed]
16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008 [PubMed]
17. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29–34. [PubMed]
18. Keane WF, Kasiske BL, O’Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol. 1988;8:261–71. [PubMed]
19. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74. [PubMed]
20. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–56. [PubMed]
21. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis. 2008 [PMC free article] [PubMed]
22. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol. 2004;15:1897–903. [PubMed]
23. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9–17. [PubMed]
24. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney International. 2005;68:766–72. [PubMed]
25. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63:654–61. [PubMed]
26. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92. [PubMed]
27. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS, Brancati FL. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis. 2003;42:256–63. [PubMed]
28. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184–91. [PubMed]
29. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Cholesterol and Recurrent Events Trial I. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International. 2005;68:237–45. [PubMed]
30. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005;46:225–32. [PubMed]
31. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Current Opinion in Nephrology & Hypertension. 2005;14:532–7. [PubMed]
32. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152–8. [PubMed]
33. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35–42. [PubMed]
34. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004:S18–21. [PubMed]
35. Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, De Jong PE, Gansevoort RT. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90. [PubMed]
36. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–10. [PubMed]